The prospects for the production and sales of proprietary Chinese medicines in the first three quarters are promising

Recently, the National Development and Reform Commission issued an analysis of the economic operation of the pharmaceutical industry from January to September of this year, showing that the pharmaceutical industry's production and sales continue to maintain steady growth, foreign trade has grown rapidly, and the industry as a whole has continued to show good momentum. The pharmaceutical industry achieved an output value of 1.1 trillion yuan, an increase of 28% year-on-year. Among them, the Chinese patent medicine manufacturing industry was 243.3 billion yuan, a year-on-year increase of 33%.

According to Guo Fanli, a research fellow in the pharmaceutical industry at China Investment Advisors, at present, the Chinese patent pharmaceutical industry maintains a rapid growth trend. The promotion of the new medical reform and the corresponding support policies of the country are the reasons for its rising sales volume, coupled with China’s preference for Chinese medicine, so that The indicators for the production and sales of Chinese patent medicines can still grow rapidly. In the first three quarters of this year, the domestic pharmaceutical industry completed a total investment of 196.4 billion yuan in fixed assets, an increase of 40% year-on-year, of which the investment in fixed assets of the Chinese patent pharmaceutical industry increased by 45% year-on-year.

Guo Fanli pointed out that in the international market, however, the Chinese patent medicine industry is still not recognized by most countries. Many countries have a mentality of rejecting Chinese medicine. The main exporting countries and regions of Chinese medicine are Asian countries such as Japan, South Korea, and Malaysia. The United States still keeps Chinese medicine outside the door. On the other hand, the complexity of the names, the large number of drugs, the unclear drug efficacy, the lack of efficacy, the repeated use of drugs, and the difficulty in selecting drugs have also become factors restricting the development of the proprietary Chinese medicine industry.

Therefore, if domestic Chinese patent medicines want to enter the international market, they should first break through the barriers of Chinese patent medicines entering the international market. In this regard, China must not only improve the regulations of the Chinese patent pharmaceutical industry and be in line with international laws and regulations, but at the same time the domestic Chinese medicine industry associations must also actively go abroad. The promotion of traditional Chinese medicine to allow foreign consumers to change their attitudes toward the rejection of traditional Chinese medicines; on the other hand, raising the industrial concentration and encouraging the restructuring of the proprietary Chinese medicine industry assets is also an important way to increase the international competitiveness of proprietary Chinese medicines.

Guo Fanli said that in the future, the prospects for the development of Chinese medicine are quite broad. Because foreign consumers have special favor for natural and green medicines, domestic plant extracts have a good export market. The demand for Chinese medicine in the Chinese market has increased. Because the level of national consumption has increased, more and more people have begun to pay attention to health care. On the other hand, the new medical reform has put forward the emphasis on pre-prevention rather than post-illness treatment, and Chinese medicine has a good effect in the treatment of chronic diseases, so the demand Increase.